Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Galcanezumab looks promising for treatment-resistant migraine

Publish date:: May 27, 2020

Key clinical point: Galcanezumab reduced the mean number of monthly migraine days at 6 months among patients who had failed prior migraine therapy.

Major finding: Treatment was associated with 5.60 fewer migraine days.

Study details: Open-label extension of a phase 3 study.

Disclosures: Eli Lilly and Company sponsored the trial. Holland Detke, PhD, is a Lilly employee.

Citation:

Detke HC et al. AAN 2020. Abstract 43625.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Neurology

HIT-6 may help track meaningful change in chronic migraine,

Vascular dementia risk particularly high in type 2 diabetes,

Blood biomarkers could help predict when athletes recover from concussions,

Mortality burden of dementia may be greater than estimated,

Multiple traits more common in difficult-to-treat patients with migraine,